Merck & Co., Inc. (MRK)
Bernstein's Courtney Breen: Merck, Novo Nordisk, others at high risk from tariffs
Courtney Breen, Bernstein senior analyst, joins CNBC's 'Money Movers' to discuss how to draw the line between tariff risks and company financials in pharmaceuticals, which companies are most at risk, and more.
Why the Market Dipped But Merck (MRK) Gained Today
In the closing of the recent trading day, Merck (MRK) stood at $89.23, denoting a +1.86% change from the preceding trading day.
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda
The filing is based on late-stage data, which shows that treatment with the subcutaneous version of MRK's Keytruda is at least as effective as the IV version.
Merck Gets EC Nod for 21-Valent Pneumococcal Jab Capvaxive
The European Commission approves MRK's pneumococcal 21-valent conjugate vaccine, Capvaxive, for pneumococcal vaccination in adults.
Merck plans US to launch subcutaneous version of Keytruda on October 1
Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates of the new version within two years.
Is Merck Stock a Bargain Buy?
Merck (MRK 0.32%) is a top healthcare company with one of the best drugs ever made in its portfolio: Keytruda. While there are concerns about its patent losses in the future, its sales are still growing.
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be closed in the second quarter of 2025.
Merck signs deal with Jiangsu Hengrui worth up to $2 billion for access to heart drug
Merck has signed a deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the companies said on Tuesday, giving the U.S. drugmaker access to an experimental heart disease drug.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Merck (MRK) stood at $94.02, denoting a -0.74% change from the preceding trading day.
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck (MRK) Advances While Market Declines: Some Information for Investors
In the closing of the recent trading day, Merck (MRK) stood at $94.71, denoting a +1.46% change from the preceding trading day.
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
